CAMSING HEALTHCARE LIMITED

(Company Registration Number: 197903888Z)
(Incorporated in the Republic of Singapore)

MATERIAL VARIANCE BETWEEN UNAUDITED AND AUDITED FULL YEAR FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 JANUARY 2025

The Board of Directors (the "**Board**") of Camsing Healthcare Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to the unaudited full year financial results announced for the financial year ended 31 January 2025 ("**FY2025**") released via the SGXNet on 1 April 2025 (the "**Unaudited Financial Statements FY2025**").

Pursuant to Rule 704(6) of the Listing Manual of the Singapore Exchange Securities Trading Limited, the Board wishes to announce and clarify that subsequent to the release of the Unaudited Financial Statements FY2025 and after the completion of the financial audit, the Company's external independent auditors, Foo Kon Tan LLP, have proposed certain adjustments and reclassifications (the "**Independent Auditors' Report**") which the management of the Company has adopted accordingly (the "**Audited Financial Statements FY2025**").

With regard to the Audited Financial Statements FY2025 and this announcement, shareholders of the Company (the "**Shareholders**") are advised to read both in conjunction with the Independent Auditors' Report released by the Company in the announcement dated 12 September 2025.

The details and explanation of the variances between the Audited Financial Statements FY2025 and the Unaudited Financial Statements FY2025 are set out below:

Adjustments to consolidated statements of financial position as follows:

	Note	Unaudited Financial Statements FY2025 S$'000	Audited Financial Statements FY2025 S$'000	Variance S$'000	Variance %
Plant and equipment	(1)	178	33	(145)	(81.5%)
Right-of-use assets	(1)	1,221	122	(1,099)	(90.0%)
Trade and other payables	(2)	(2,163)	(2,496)	(333)	15.40%
Borrowings (non-current)	(3)	(2,105)	(1,949)	156	(7.4%)

Adjustments to consolidated statements of comprehensive income as follows:

	Note	Unaudited Financial Statements FY2025 S$'000	Audited Financial Statements FY2025 S$'000	Variance S$'000	Variance %
Other income	(4)	2,046	1,869	(177)	(8.70)
Marketing and distribution expenses	(5)	(3,879)	(3,374)	505	(13.0%)
General and administrative expenses	(5)	(1,447)	(1,954)	(507)	35.0%
Impairment loss on plant and equipment and right-of-use assets	(1)	-	(1,242)	(1,242)	N.M
Loss before taxation		(881)	(2,302)	(1,421)	N.M

Adjustments to statements of financial position for Company as follows:

	Note	Unaudited Financial Statements FY2025 S$'000	Audited Financial Statements FY2025 S$'000	Variance S$'000	Variance %
Investment in subsidiaries	(6)	2,332	-	(2,332)	(100%)
Borrowings (non-current)	(7)	(1,000)	(918)	82	(8.2%)

Adjustments to consolidated statements of cash flows as follows:

	Note	Unaudited Financial Statements FY2025 S$'000	Audited Financial Statements FY2025 S$'000	Variance S$'000	Variance %
Loss before taxation		(881)	(2,302)	(1,421)	N.M
Impairment loss on plant and equipment	(1)	-	145	145	N.M
Impairment loss on right-of-use assets	(1)	-	1.097	1,097	N.M
Payables written back	(2)	(575)	(244)	331	(135.7%)
Unwinding of interest on non-current loans	(7)	-	(156)	(156)	N.M
Operating loss before working capital changes		(1,323)	(1,326)	(3)	N.M

Explanatory notes:

(1) Additional impairment loss on the Group's plant and equipment and right-of-use assets was due to impairment loss recognised for certain under-performing outlets.

(2) Based on consultations with the Company's legal counsel, management assessed that claims in relation to certain balances owing by Nature's Farm Pte Ltd to I-Nitra Consulting Limited ("**I-Nitra**") had not yet become time-barred pursuant to the Limitation Act 1959 as at 31 January 2025. Accordingly, payables previously written back of $0.3 million was reversed.

(3) Decrease in borrowings mainly due to the unwinding of interest on non-current loans.

(4) Decrease in other income mainly due to the reversal of I-Nitra write-back of payable which offset by the unwinding of interest on non-current loans.

(5) Being reclassification of accounts.

(6) Management engaged an independent valuer to determine the recoverable amount of the Company's investments in subsidiaries, and the impairment assessment had not been completed on the date of the unaudited results announcement. Following the completion of the impairment assessment by the independent valuer, an impairment loss of $2.3 million was

recognised to the Company's profit or loss to write-down the carrying amount to the recoverable amount of Nil as determined by the independent valuer.

(7) Decrease in borrowings mainly due to the unwinding of interest on non-current loans.

The Board confirms that to the best of its knowledge, all material disclosures, facts and information have been provided and announced and are not aware of any facts, information or disclosures, the omission of which would make any statement in this announcement or disclosures misleading.

Shareholders are advised to exercise caution when dealing in the shares of the Company. Persons who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisors.

BY ORDER OF THE BOARD

Duanmu Xiaoyi
Executive Director
12 September 2025